Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The bone metastasis in solid tumors market is expanding due to rising incidences of metastasizing solid tumors like breast, prostate, lung cancer, and renal cell carcinoma. This growth is fueled by ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

Former President Joe Biden's office confirmed on Sunday that he was diagnosed with an "aggressive form" of prostate cancer. "Last week, President Joe Biden was seen for a new finding of a prostate ...